Entyvio is a medicine used to treat adult patients with ulcerative colitis (a disease causing inflammation and ulcers in the lining of the bowel) or Crohn’s disease (a disease causing inflammation of the digestive tract). Entyvio is used to treat moderately to severely active disease when conventional therapy or medicines called TNF\-alfa antagonists are ineffective, no longer effective, or cannot be tolerated by the patient. Entyvio is also used for the treatment of adult patients with ongoing (chronic) pouchitis (a disease causing inflammation of a pouch created during certain types of surgery where the large intestine in people with ulcerative colitis is removed). Entyvio is used to treat moderately to severely active disease when antibiotic therapy is ineffective or no longer effective. Entyvio contains the active substance vedolizumab.
Therapeutic Indication
**Ulcerative colitis** Entyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNF?) antagonist. **Crohn’s disease** Entyvio is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNF?) antagonist. **Pouchitis** Entyvio is indicated for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.
Therapeutic Area (MeSH)
ATC Code
N/A
ATC Item
N/A
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
EMA Name
Entyvio
Medicine Name
Entyvio
Aliases
N/ANo risk management plan link.
